This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Strong Buys at New Highs
by David Bartosiak
Dave's Daily Dive and five new strong buys breaking out
Here's Why You Should Steer Clear of Mednax (MD) for Now
by Zacks Equity Research
Over the past 6 six months, shares of Mednax (MD) have gained 4.9%., underperforming the 9.8% increase logged by the Zacks categorized Medical - Hospital industry.
Integra LifeSciences Expands Cadence System Commercially
by Zacks Equity Research
Integra LifeSciences Holdings Corporation (IART), a global medical technology company, recently announced full commercial expansion of its Cadence Total Ankle System.
Intuitive Surgical Hits 52-Week High on Multiple Positives
by Zacks Equity Research
Shares of leading provider of robotic-assisted surgery, Intuitive Surgical, Inc. (ISRG) rallied to a new 52-week high of $770.28 on Mar 28, closing a tad lower at $764.47.
Akers Receives Cholesterol Test Kit Order from First Check
by Zacks Equity Research
Akers Biosciences, Inc. (AKER) announced that it has received an initial order under the distribution agreement for its rapid cholesterol self-test kit.
Renewed Obamacare Repeal Effort Sends Hospital Stocks Down
by Benjamin Rains
Hospital stocks have dipped again amid reports that House Republicans will continue to pursue their health care reform plan in 2017.
Obamacare Holds Ground: 3 Medical Device Stocks to Gain
by Zacks Equity Research
Republican leaders have failed to play their "Trump card" this time, courtesy of the pullback of the Republican healthcare bill, the American Health Care Act (ACHA), which was designed to repeal the Affordable Care Act (ACA) or Obamacare.
Henry Schein (HSIC) Poised on Solid Growth, Risks Remain
by Zacks Equity Research
On Mar 27, we issued an updated research report on Melville, NY-based Henry Schein, Inc. (HSIC).
BioScrip (BIOS) Stock Declines on Dull Q1 EBITDA Outlook
by Zacks Equity Research
Bioscrip, Inc.'s (BIOS) shares witnessed a 2.2% fall in yesterday's trading session, closing at $1.78.
Evolent Health (EVH) Prices 7.5M Follow-On Share Offering
by Zacks Equity Research
Evolent Health, Inc. (EVH) announced the pricing of its follow-on public offering of 7.5 million shares of Class A common stock at $21.25 per share.
LifePoint Grows Inorganically Yet Stock Suffers: Here's Why
by Zacks Equity Research
Despite its efforts to grow inorganically, LifePoint's shares returned 15.2% compared with a 31% gain for the Zacks categorized Medical Hospital industry over the past three years.
DexCom Gains as CMS Announces Criteria for G5 Mobile CGM
by Zacks Equity Research
The Centers for Medicare & Medicaid Services published an article clarifying the criteria for coverage of its DexCom (DXCM) G5 Mobile CGM system for patients with diabetes and on intensive insulin therapy.
Align Partners Zfx GmbH to Expand iTero Scanner Business
by Zacks Equity Research
Align Technology Inc. (ALGN) announced a non-exclusive agreement with digital prosthetic solutions maker, Zfx GmbH on iTero Element intraoral scanners.
VWR Corp Acquires EPL Archives, Improves Customer Service
by Zacks Equity Research
VWR Corporation (VWR) recently acquired the international biorepository services organization, EPL Archives, Inc.
5 Biggest Winners from the Obamacare Replacement Bill Pushback
by Swarup Gupta
This setback was largely an outcome of the lack of consensus among various factions of the GOP.
PetMed Express' New Order Sales Disappoint, Competition Rife
by Zacks Equity Research
On Mar 23, we issued an updated research report on Pompano Beach, FL-based PetMed Express, Inc. (PETS).
Ecolab (ECL) Teams Up with Microsoft to Upgrade Water Tool
by Zacks Equity Research
Ecolab Inc. (ECL) announced that it has collaborated with Microsoft Corp. (MSFT) to upgrade its financial-modeling tool, Water Risk Monetizer.
Medidata Clinical Cloud Selected for AML Master Trial by LLS
by Zacks Equity Research
Medidata Solutions Inc. (MDSO) announced that The Leukemia & Lymphoma Society selected Medidata Clinical Cloud platform for diagnosis and treatment of acute myeloid leukemia (AML) through a clinical trial known as the Beat AML Master Trial.
Zacks Industry Outlook Highlights: Quidel, OraSure Technologies, ResMed, Inogen and Masimo
by Zacks Equity Research
Zacks Industry Outlook Highlights: Quidel, OraSure Technologies, ResMed, Inogen and Masimo
The Cooper Companies Hits 52-Week High on Multiple Positives
by Zacks Equity Research
Shares of Pleasanton, CA-based The Cooper Companies (COO) rallied to a new 52-week high of $202.70 on Mar 23, closing a tad lower at $199.70.
Walgreen Boots Buyout of Rite Aid Delayed, Other Woes Remain
by Zacks Equity Research
On Mar 24, we issued an updated research report on Illinois-based leading pharmacy-led, health and wellbeing enterprise, Walgreens Boots Alliance, Inc. (WBA).
Medtronic's (MDT) CoreValve Evolut Pro Receives FDA Approval
by Zacks Equity Research
Medical device major Medtronic plc (MDT) recently announced that it has received the FDA approval for its CoreValve Evolut PRO valve.
Merit Medical (MMSI) Prices 4.5M Follow-On Share Offering
by Zacks Equity Research
Merit Medical Systems, Inc. (MMSI) announced that it has priced its follow-on public offering of 4.5 million shares of common stock at $28.25 per share.
Obamacare Repeal Vote Looms: What Investors Need to Know
by Madeleine Johnson
Investors' eyes will be focused on Congress today, as the House is scheduled to vote on the American Healthcare Act (AHCA). Whether you think it???s "Obamacare Lite" or "dead on arrival" like Sen. Rand Paul, the AHCA has certainly made an impact on Wall Street, as well as the entire healthcare industry since its announcement.
Should HCA Holdings (HCA) Stock Be in Your Portfolio Now?
by Zacks Equity Research
HCA Holdings Inc. (HCA) stock has gained 8.12% in the last one year, outperforming the Zacks categorized Medical-Hospitals industry, which registered an increase of only 1.26%.